ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities.
Zamorano Cuervo N, Grandvaux N. · 2020
Read ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. by Zamorano Cuervo N, Grandvaux N. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7652413.txt.
Description
Zamorano and Grandvaux review ACE2 as the entry receptor for SARS-CoV-2 and its role in related illnesses. Knowing the entry receptor is key to virus behavior. It shapes spread, tissue targets and disease course.
Early evidence pointed to ACE2 for virus entry. The review sums up proof and its limits. Gaps that remain in ACE2 knowledge are named. Expression of ACE2 across tissues is covered in depth. Its role is weighed beside illnesses tied to poor outcomes. Those include hypertension, diabetes and obesity in patients. Heart disease, COPD and smoking status also feature. Possible co-receptors and attachment factors are discussed. Names include neuropilins, heparan sulfate and sialic acids. Alternate receptors such as CD147 are also weighed.
Catalog record
| CREATOR | Zamorano Cuervo N, Grandvaux N. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 115 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |